C57BL/6JCya-Slc22a1em1flox/Cya
Common Name
Slc22a1-flox
Product ID
S-CKO-05096
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-20517-Slc22a1-B6J-VA
Status
When using this mouse strain in a publication, please cite “Slc22a1-flox Mouse (Catalog S-CKO-05096) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Slc22a1-flox
Strain ID
CKOCMP-20517-Slc22a1-B6J-VA
Gene Name
Product ID
S-CKO-05096
Gene Alias
Lx1, Oct1, Orct, Orct1
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 17
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000024596
NCBI RefSeq
NM_009202
Target Region
Exon 4
Size of Effective Region
~1.9 kb
Overview of Gene Research
Slc22a1, also known as the gene encoding the broad selectivity transporter hOCT1, is expressed in most epithelial barriers and different drug target cells [2]. It contributes to drug pharmacokinetics and pharmacodynamics, mediating the translocation of various drugs, such as metformin, anticancer, antiviral, anti-inflammatory agents [2].
In chronic myeloid leukemia (CML), carriers of SLC22A1 rs628031A allele or rs683369G allele are associated with a lower major molecular response (MMR) rate to imatinib treatment [1]. In Mexican women, genetic variants in SLC22A1 are related to serum lipid levels, with certain genotypes and haplotypes associated with changes in cholesterol and lipoprotein levels [3]. In children with acute lymphoblastic leukemia in the Amazon region, the SLC22A1 gene variant is associated with a higher risk of severe infectious toxicity during treatment [4].
In conclusion, Slc22a1 plays a crucial role in drug disposition and therapeutic responses. Its genetic variants are associated with different disease-related outcomes, including drug response in CML, lipid metabolism in Mexican women, and treatment-related toxicity in childhood leukemia. Understanding Slc22a1 through genetic models helps uncover its role in these biological processes and disease conditions.
References：
1. Cargnin, Sarah, Ravegnini, Gloria, Soverini, Simona, Angelini, Sabrina, Terrazzino, Salvatore. 2018. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. In Pharmacological research, 131, 244-254. doi:10.1016/j.phrs.2018.02.005. https://pubmed.ncbi.nlm.nih.gov/29427770/
2. Arimany-Nardi, C, Koepsell, H, Pastor-Anglada, M. 2015. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. In The pharmacogenomics journal, 15, 473-87. doi:10.1038/tpj.2015.78. https://pubmed.ncbi.nlm.nih.gov/26526073/
3. Cahua-Pablo, José Ángel, Gómez-Zamudio, Jaime Héctor, Reséndiz-Abarca, Carlos Alberto, Zubillaga-Guerrero, Ma Isabel, Flores-Alfaro, Eugenia. 2021. Genetic variants in SLC22A1 are related to serum lipid levels in Mexican women. In Lipids, 57, 105-114. doi:10.1002/lipd.12334. https://pubmed.ncbi.nlm.nih.gov/34927264/
4. Fernandes, Sweny de S M, Leitão, Luciana P C, Cohen-Paes, Amanda de N, Santos, Sidney E B Dos, Santos, Ney P C Dos. 2022. The Role of SLC22A1 and Genomic Ancestry on Toxicity during Treatment in Children with Acute Lymphoblastic Leukemia of the Amazon Region. In Genes, 13, . doi:10.3390/genes13040610. https://pubmed.ncbi.nlm.nih.gov/35456416/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.